Latest Australian Government News

Nufarm’s 2025 AGM revealed a resilient FY24 performance despite industry headwinds, with strategic investments in omega-3 canola, biofuels, and cost-saving initiatives setting the stage for growth in FY25.

Entyr Limited has received a $3.79 million R&D tax incentive payment for its innovative thermal desorption project targeting rubber waste, reinforcing its position in sustainable tyre recycling technology.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

Betashares Capital Ltd has announced the final distribution amounts for its suite of funds for the January 2025 period, outlining key dates and eligibility for unitholders.

SkyCity Entertainment Group has resolved a decade-long dispute over casino duty calculations with South Australia’s Treasurer, agreeing to a $38.1 million settlement that ends ongoing legal proceedings.

Kula Gold reports promising shallow gold intersections at Mt Palmer and secures government co-funding, while launching a $1.6 million entitlement offer to fuel further exploration.

Asra Minerals has successfully completed Phase 1 drilling at its Leonora North and South gold projects, confirming significant gold mineralisation and setting the stage for an expanded Phase 2 program in March 2025.

Alchemy Resources Limited has received FIRB approval for its joint venture with JOGMEC on the Karonie Gold-Lithium Project, advancing exploration activities with significant soil sampling and drilling underway.

Gold Hydrogen Ltd has reported the detection of rare Helium-3 in its Ramsay Project gas samples, alongside record-high helium purities, while expanding its exploration footprint in South Australia.

Tambourah Metals reports significant high-grade gold assay results from its Pilbara projects and secures government grants to accelerate drilling programs across multiple prospects.

Papyrus Australia has taken significant strides in Q4 2024, signing a joint venture terms sheet in Vietnam, appointing new board members, and securing R&D tax incentives, positioning itself for expanded commercialization.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.